Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.
An G, Acharya C, Deng S, Yi S, Xu Y, Qin X, Sui W, Li Z, Shi L, Zang M, Feng X, Hao M, Zou D, Zhao Y, Qi J, Cheng T, Ru K, Wang J, Tai YT, Qiu L.
An G, et al. Among authors: qiu l.
Exp Hematol. 2015 Mar;43(3):168-176.e2. doi: 10.1016/j.exphem.2014.11.004. Epub 2014 Nov 20.
Exp Hematol. 2015.
PMID: 25462022
Free article.
Clinical Trial.